Introduction {#sec1}
============

Infectious bursal disease virus (**IBDV**) belongs to the family *Birnaviridae*, within the genus *Avibirnavirus*. Two serotypes of IBDV are known: serotype 1, further categorized into classical, attenuated, very virulent, and antigenic variant strains, and serotype 2, including only avirulent strains. New genetic lineages of IBDV continuously emerge worldwide ([@bib19]) and possess different antigenic and pathogenic characteristics ([@bib17]; [@bib5]; [@bib4]). Independent of the pathogenicity of the strain involved and the severity of caused clinical signs, IBDV infection in chickens is always associated with damage to the bursa of Fabricius and immunosuppression ([@bib29]; [@bib25]; [@bib30]; [@bib16]) which is more severe if the infection occurs during the first 3 wk of age in birds with low levels of maternally derived antibodies.

Infectious bursal disease (**IBD**) has a relevant economic impact on poultry production around the world because of the immunosuppression caused in chickens leading to an increased susceptibility to secondary infections and a failure of the vaccination programs applied ([@bib1]; [@bib22]). As IBDV is a nonenveloped virus, very resistant to commonly used disinfectants, biosafety measures applied in poultry farms are normally not sufficient to prevent persistence of the virus in the environment. Therefore, IBD control relies mostly on vaccination. The vaccines currently commercially available include traditional live-attenuated and inactivated vaccines; immune-complex vaccines, which contains a combination of live-attenuated IBDV and specific antibody; and vaccines consisting of viral constructs of herpesvirus of turkeys (**HVT)** genetically engineered to express the IBDV surface protein VP2 ([@bib19]). Live virus strains included in the formulation of certain IBD vaccines, although attenuated, are reported to be able to induce in vaccinated birds macroscopic and microscopic changes of the bursa of Fabricius similar to those caused by pathogenic viruses ([@bib11]). The death of lymphocytes caused by the virus, also through apoptotic phenomena, can lead to the risk that the vaccine virus itself causes immunosuppression.

Infectious bronchitis (**IB**) is a highly contagious viral respiratory disease of chickens caused by an *avian coronavirus* (**IBV**) characterized by high substitution and recombination rates, which have led to the emergence of several genotypes and lineages over time ([@bib7]; [@bib15]; [@bib34]; [@bib6]; [@bib10]; [@bib18]). The disease is widely controlled by the application of multifarious vaccination protocols ([@bib8]) mainly based on live vaccines, which stimulate systemic and upper respiratory tract immunity (either humoral or cell-mediated). Immunity conferred by IBV vaccines can be impaired by immunodeficiency caused by viral agents such as IBDV ([@bib33]).

The aim of this project was to investigate, through 2 animal trials, the impact of the administration of a dual recombinant herpes virus of turkey (**rHVT**) construct vaccine, expressing VP2 protein of IBDV and F protein of Newcastle disease virus, or an immune-complex IBDV vaccine on the immune system of day-old specific pathogen free (**SPF**) broiler chickens. In particular, the integrity of bursa of Fabricius (trial 1) and the immune response of the vaccinated birds to different IBDV vaccines and live IBV vaccines, through serology and flow cytometry (**FMC**) analysis of mononuclear cells in the Harderian glands, trachea, and spleen (trial 2), were evaluated.

Materials and methods {#sec2}
=====================

Birds {#sec2.1}
-----

SPF broiler chicken eggs (Hybro genetic) were supplied by GD Animal Health (Deventer, the Netherlands) and hatched in the animal facility of the Avian Pathology Service of the Department of Veterinary Medical Sciences (University of Bologna). One-hundred SPF chicks were used and housed in pens or isolators for the duration of the study. Food and water were provided *ad libitum*.

Vaccines {#sec2.2}
--------

The following commercially available vaccines were administered in accordance to the guidelines of the manufacturers: a dual rHVT construct vaccine (designated **rHVT-ND-IBD**) which contains IBDV-VP2 and NDV-F genes (Innovax-ND-IBD, MSD Animal Health); an immune-complex IBDV vaccine (designated **IMMUNE-IBDV**) consisting a live intermediate plus IBDV strain (2512-IBDV) conjugated with hyperimmune serum against IBDV (Cevac Transmune, Ceva Salute Animale); a cell-associated HVT-FC126 strain (designated HVT) (Nobilis Marexine CA 126, MSD Animal Health); an IBV live vaccine based on the MA5 strain (Nobilis IB Ma5, MSD Animal Health); and an IBV live vaccine based on the 4/91 strain (Nobilis IB 4-91, MSD Animal Health).

Trial 1 {#sec2.3}
-------

### Experimental plan {#sec2.3.1}

Sixty male birds were randomly divided in groups, housed in pens, and vaccinated as reported in [Table 1](#tbl1){ref-type="table"} . Briefly, chickens were vaccinated via the subcutaneous route at 1 D of age with rHVT-ND-IBD (designated rHVT-ND-IBD group, n = 24 birds), IBD immune complex vaccine and HVT vaccine (designated IMMUNE-IBDV group, n = 24 birds), or vaccinated with HVT vaccine and not vaccinated for IBDV (designated control group, n = 12 birds). From each of the groups rHVT-ND-IBD and IMMUNE-IBDV, 14, 5, and 5 birds, were euthanized, at 14, 28, and 35 D of age, respectively, weighed and subjected to postmortem examination. Bursa of Fabricius of the birds were collected and weighed for the subsequent calculation of the bursa:body weight (**B:BW**) ratios. From the control group, 4 birds for each sampling date were analogously processed.Table 1Vaccination plans applied to birds in trial 1 and trial 2.GroupsNo. of birdsVaccinationsAt 1-day-oldAt 14 D of lifeTrial 1 Control12HVTNot done rHVT-ND-IBD24rHVT-ND-IBDNot done IMMUNE-IBDV24IMMUNE-IBDV + HVTNot doneTrial 2 Control6HVTIBV Ma5+4/91 rHVT-ND-IBD17rHVT-ND-IBDIBV Ma5+4/91 IMMUNE-IBDV17IMMUNE-IBDV + HVTIBV Ma5+4/91

### Bursa:body weight ratio {#sec2.3.2}

B:BW ratios were calculated according to the following formula: B:BW ratio = \[bursa weight (g)/body weight (g)\] × 1,000.

Trial 2 {#sec2.4}
-------

### Experimental plan {#sec2.4.1}

Forty female birds were randomly divided in groups, housed in poultry isolators, and vaccinated as reported in [Table 1](#tbl1){ref-type="table"}. Briefly, chickens were inoculated at one day of age via subcutaneous route with rHVT-ND-IBD (designated rHVT-ND-IBD group, n = 17 birds), with IBD immune-complex and HVT vaccines (designated IMMUNE-IBDV group, n = 17 birds), or not IBDV vaccinated (designated control group, n = 6 birds). At 14 D of life, all the experimental groups were eye-drop vaccinated for IBV with MA5 and 4/91 vaccines. At 0, 7, 14, 21, and 28 D after IBV vaccination, birds were bled, and their sera were tested for IBV antibody. At 28 D after IBV vaccination, birds were euthanized and necropsied for collection of Harderian glands, trachea, and spleen (0.3 g ±10%). Tissues were individually stored in MACSTissue Storage Solution (Miltenyi Biotec, Bergisch Gladbach, Germany) at + 5°C, for a maximum of 24 h, until processing for mononuclear cells isolation and FMC analysis.

### Serology {#sec2.4.2}

Anti-IBV antibody titers were determined in serum samples using a commercial kit (IDEXX IBV Ab Test-IDEXX), following the manufacturer\'s instructions.

### Mononuclear cells isolation {#sec2.4.3}

To obtain mononuclear cells for subsequent FMC analysis, tissues were dissociated using the gentleMACSTMOcto Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany). Spleen samples and whole Harderian glands were first suspended in 5 mL of PBS and subsequently dissociated for 30 s (program m_spleen_01_01) and 28 s (program MultiA_01), respectively. Tracheas were cut into 2- to 3-mm slices, suspended in 8 mL of Collagenase type IV solution (RPMI-1640, 1% HEPES, 1% Penicillin-Streptomycin, 200 Collagen Digestion Units/mL; Sigma Aldrich, Hamburg, Germany), and then dissociated for 45 min at 37°C (program 37C_MULTIA_01). Dissociated cells were filtered (70-μm mesh) and centrifuged in PBS at 300 *g* for 10 min. The supernatants were discarded, and cell pellets were resuspended in 4 mL of PBS. Mononuclear cells were collected from interphase after density gradient centrifugation over Ficoll Paque Plus (GE Healthcare, Little Chalfont, UK) at 400 g for 30 min, washed twice, resuspended in 1 mL of PBS, and counted. For each subsequent FMC analysis, 10^6^ cells were used.

### Flow cytometry {#sec2.4.4}

In the whole, FCM analyses were performed on mononuclear cells obtained by 40 spleens, 40 Harderian glands, and 40 tracheas. Mononuclear cells were stained with antichicken undiluted appropriate fluorochrome-conjugated antibodies, for 30 min at 4°C in the dark, against CD45 leukocytes (CD45-APC), CD8 cytotoxic T cells (CD8-FITC), CD4 T-helper cells (CD4-PE), and Bu1A B-cells (Bu1A-FITC) ([Table 2](#tbl2){ref-type="table"} ) ([@bib31]). A multiparametric experiment was carried out as reported in [Table 3](#tbl3){ref-type="table"} . Unstained controls to evaluate inherent background or autofluorescence were obtained omitting primary antibodies but adding only Viability 405/452 Fixable Dye (VioBlue, Miltenyi Biotec, Bergisch Gladbach, Germany) used to distinguish viable and dead cells. To compensate for spectral overlap, single staining for each antibody and unstained cell samples was used. After incubation, cells were washed twice and resuspended in 200 μL of PBS then analyzed by using MacsQuant Analyzer10 (Miltenyi Biotec, Bergisch Gladbach, Germany) equipped with 3 lasers (405, 488, and 638 nm). This flowcytometer quickly performs absolute cell counting without the need for counting beads or cell staining. Data were analyzed using the Flowlogic software (Miltenyi Biotec, Bergisch Gladbach, Germany), and gates applied for populations discrimination were set manually based on control samples. A uniform hierarchical gating strategy was used throughout all samples. To start, cellular events were discriminated from debris using forward (**FSC-A**) and side scatter (**SSC-A**). Doublets have been excluded for analysis by FSC-area and height (FSC-A/FSC-H), and dead cells were kept out on the basis of gate set in samples stained with VioBlue. The single cells were further analyzed for expression of CD45 marker to select leukocyte from other events. CD8, CD4, and Bu1A positive cells were identified among CD45-positive population.Table 2Details of antichicken fluorochrome-conjugated antibodies used in the FMC analysis on mononuclear cells.NameSpecificityCloneFluorochromeStained cellsSupplierCD45-APCchCD45LT40APCLeukocytesInvitrogenCD8-FITCchCD811-39FITCCytotoxic T cellsBioradCD4-PEchCD42-35PET-helper cellsThermo Fisher ScientificBu-1A-FITCBu1L22FITCB-cellsInvitrogenTable 3Multicolor panel design and pipetting scheme for staining---fluorochromes and filters details.SampleCD45-APCCD8-FITCCD4-PEBu1A-FITCVioBlueExitation max/emission max (nm)Filter (nm)Control////10 μL405/452450/50 V1Single color staining0.5 μL////651/662655-730 R1Single color staining/0.5 μL///490/525525/50 B1Single color staining//0.5 μL//565/575585/40 B2Single color staining///0.5 μL/490/525525/50 B1Multicolor panel A0.5 μL0.5 μL0.5 μLMulticolor panel B0.5 μL//0.5 μL/

Statistical Analysis {#sec2.5}
--------------------

Data were analyzed using R version 3.5.1 (2018-07-02) (2018 The R Foundation for Statistical Computing). Data are expressed as mean ± standard deviation; Shapiro Wilk test was used to test normality. One-way ANOVA and Tukey post hoc test were performed to assess the difference between groups. Significance was set at *P* \< 0.05.

Ethical Statement {#sec2.6}
-----------------

The experimental trials were performed in agreement with the European regulations on animal experiments and animal welfare (EU Directive 2010/63/EU) and after obtaining approval for the animal procedures from the Italian Ministry of Health (permit number 478/2016-PR).

Results {#sec3}
=======

Trial 1 {#sec3.1}
-------

### B:BW ratio {#sec3.1.1}

Mean B:BW ratios per experimental group and day of sampling are reported in [Figure 1](#fig1){ref-type="fig"} . At 14, 28, and 35 D after IBDV vaccination, the mean B:BW ratios of the group of birds vaccinated with the immune-complex vaccine (IMMUNE-IBDV group) were significantly lower than the mean B:BW ratios of the group of birds vaccinated with rHVT-ND-IBD vaccine (rHVT-ND-IBD group) and the group not IBDV vaccinated (control group) (*P* \< 0.05).Figure 1Bursa:body weight ratios analysis---trial 1. Mean bursa:body weight ratios (±standard deviations) of the not-IBDV vaccinated group (control group, n = 12), of the rHVT-ND-IBD vaccinated group (rHVT-ND-IBD group, n = 24 birds), and of the immune-complex vaccinated group (IMMUNE-IBDV group, n = 24 birds), by day of sampling. Different letters indicate the difference is statistically significant (*P* \< 0.05).

### Post-mortem examination {#sec3.1.2}

At postmortem examination, birds of the IMMUNE-IBDV group have shown a macroscopically evident atrophy of the bursa of Fabricius from 14 D after IBDV vaccination until the end of the trial compared with the birds of the other experimental groups.

Trial 2 {#sec3.2}
-------

### Serology {#sec3.2.1}

ELISA anti-IBV antibody titers detected in experimental groups are graphically reported in [Figure 2](#fig2){ref-type="fig"} . From 7 D after IBV vaccination, anti-IBV antibodies have been detected in all groups with increasing titers up to the end of the trial. At 14 and 21 D after IBV vaccination, birds of the group IBDV vaccinated with immune-complex vaccine (IMMUNE-IBDV group) showed significantly lower mean IBV antibody titers than birds of the rHVT-ND-IBD group and of the not--IBDV vaccinated group (Control group) (*P* \< 0.05). At 28 D after IBV vaccination, differences were statistically significant between groups rHVT-ND-IBD and IMMUNE-IBDV, showing the last group a lower mean antibody titer (*P* \< 0.05).Figure 2IBV Serology---trial 2. Mean IBV antibody titres (±standard errors) detected in the not-IBDV vaccinated group (control group, n = 6), in the rHVT-ND-IBD vaccinated group (rHVT-ND-IBD group, n = 17 birds), and in the immune-complex vaccinated group (IMMUNE-IBDV group, n = 17 birds), according to days post-IBV vaccination. Different letters indicate that the difference among groups at each experimental point is statistically significant (*P* \< 0.05).

### Flow cytometry analysis {#sec3.2.2}

At 28 D after IBV vaccination, mononuclear cells from the spleen, Harderian gland, and trachea of birds of all groups were analyzed by FMC using different staining panels ([Table 3](#tbl3){ref-type="table"}) and a uniform hierarchical gating strategy as shown in [Figure 3](#fig3){ref-type="fig"} . On average 144,234; 29,879; and 68,383 events were analyzed for spleens, Harderian glands, and tracheas, respectively. Percentage of leukocytes was expressed as CD45^+^/total cells ([Figure 4](#fig4){ref-type="fig"} A). CD8, CD4, and Bu1A positive cells were identified among CD45-positive population (expressed as percentage of CD4+/CD45+, CD8+/CD45+, and Bu-1A+/CD45+ cells) ([Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}B, [5](#fig5){ref-type="fig"}A and [5](#fig5){ref-type="fig"}B).Figure 3Gating strategy in multicolor flow cytometry analysis. Representative cytograms (A, E, I, D, N), FSC-A/FSC-H plot (B), and single parameter histograms (C, F, G, H, L, M) concerning mononuclear cells in spleen samples. Debris were discarded using forward (FSC-A) and side scatter (SSC-A) (A, E, I). Doublets were excluded by FSC-A/FSC-H discrimination gate (B). Live cells were selected based on gate set in samples stained with VioBlue for further analysis (C). Live cells showed in green on the cytogram (D). Singlets were analyzed for CD45 (F, L), CD8 (G), CD4 (H), and Bu-1A (M) expression. CD45-positive cells showed in pink on the cytogram (N).Figure 4Mononuclear cells characterization (CD45+ and Bu1-A+) by flow cytometry analysis---trial 2. Percentage of CD45+/total cells (A) and Bu-1A+/CD45+ cells (B) in the spleen, Harderian gland, and trachea at 28 D after IBV vaccination in the not--IBDV vaccinated group (control group, n = 6), in the rHVT-ND-IBD vaccinated group (rHVT-ND-IBD group, n = 17 birds), and in the immune-complex vaccinated group (IMMUNE-IBDV group, n = 17 birds). Horizontal lines represent median; boxes represent 25-75 percentile; whiskers represent min-max; dots represent outliers.Figure 5Mononuclear cells characterization (CD4+ and CD8+) by flow cytometry analysis---trial 2. Percentage of CD4+/CD45+ cells (A), CD8+/CD45+ cells (B), and CD4+/CD8+ ratio (C) obtained by FMC analysis, in the spleen, Harderian gland, and trachea at 28 D after IBV-vaccination in the not--IBDV vaccinated group (control group, n = 6), in the rHVT-ND-IBD vaccinated group (rHVT-ND-IBD group, n = 17 birds), and in the immune-complex vaccinated group (IMMUNE-IBDV group, n = 17 birds). Horizontal lines represent median; boxes represent 25-75 percentile; whiskers represent min-max; dots represent outliers. Different superscripts indicate significant difference for *P* \< 0.05.

Results showed that the mean relative number of Bu-1A and CD4 positive cells did not vary significantly between IBDV-vaccinated and not--IBDV vaccinated groups (*P* \> 0.05) in all the examined tissues ([Figures 3](#fig3){ref-type="fig"}B and [4](#fig4){ref-type="fig"}A). Conversely, statistically significant differences were observed between the groups in the mean relative number of CD8+ cells, which was higher in the IMMUNE-IBDV group, in spleen and trachea, than in the rHVT-ND-IBD group (*P* \< 0.05), and also in the Harderian gland compared to the control group (*P* \< 0.05) ([Figure 4](#fig4){ref-type="fig"}B). Moreover, the mean CD4+/CD8+ ratio was calculated and resulted to be significantly lower in the tracheas of the IMMUNE-IBDV group than in the tracheas of the control group (*P* \< 0.05) ([Figure 4](#fig4){ref-type="fig"}C). No other statistically significant differences in the mean CD4+/CD8+ ratios were observed between groups (*P* \> 0.05).

Discussion {#sec4}
==========

In the present study, we compared, in 2 animal trials, the effects of vaccination of SPF broiler chickens with different IBD vaccines, namely an rHVT-ND-IBD construct vaccine or an IBDV immune-complex vaccine, on the integrity of the bursa of Fabricius and the immune response to live IBV vaccination.

In the first experiment, the impact of the different IBDV vaccines was evaluated at 14, 28, and 35 D after IBDV vaccination, by B:BW ratios comparison between groups. Birds of the group vaccinated with the immune-complex vaccine showed bursal atrophy represented by significantly lower B:BW ratios, at all time points of sampling, when compared to the non--IBDV vaccinated birds or to the group vaccinated with the rHVT-ND-IBD construct. These results confirm previously published reports where different live IBDV vaccines are shown to cause bursal atrophy and moderate to severe bursal lesions under experimental or field conditions ([@bib32]; [@bib11]; [@bib9]).

Moreover, no evidence of alteration of the bursa of Fabricius was shown during trial 1 in birds vaccinated with the rHVT-ND-IBD construct; these data expand the already reported evidence about the safety of HVT vaccine constructs developed to express foreign antigens ([@bib35]; [@bib26]; [@bib3]).

The IBDV immune-complex vaccine effect on bursa of Fabricius may correlate with a decrease in the ability to mount an adequate humoral immune response and with an impairment of the immune response to vaccinations as previously reported after live IBDV vaccination application ([@bib27]; [@bib12]; [@bib24]; [@bib22]).

To confirm this hypothesis, in the second trial, antibody titers after IBV vaccination had a significantly lower increase in the group vaccinated with the IBDV immune-complex vaccine than in the other experimental groups. Controversially, in this group, despite the significantly lower level of circulating IBV-induced antibodies, the relative amount of Bu-1A--positive lymphocytes, measured by cytofluorimetric analysis, was not impaired in all the examined organs. This feature could be attributed to postinfection repopulation of bursal follicles with B lymphocyte unable to mount an appropriate antibody response, which has been reported at early age of chicken after infection with virulent IBDV ([@bib36]).

Interestingly, birds belonging to the group vaccinated with immune-complex vaccine showed a significantly higher mean percentage of CD8+ T cells than both the other groups, in the spleen and trachea and, compared with the control group, also in the Harderian glands. During the immune response, CD8+ T cells first recognize the antigen peptides associated to major histocompatibility class I complex then proliferate and differentiate into armed antigen-specific cytotoxic T lymphocytes (**CTLs**). CTLs exert their protective effect via a range of effector mechanisms and cytolytic pathways that have been demonstrated to clear viruses infection ([@bib2]). CTLs were suggested also to contribute to lesion development in the bursa after IBDV infection ([@bib12]; [@bib23]) and in the late stage of the infection. [@bib13] ([@bib13]) observed that IBDV exposed birds showed a higher lymphocyte subpopulation of CD8+ T cells than virus-free birds, in the bursa and in the spleen up to 22 D after IBDV infection. Furthermore, [@bib14] ([@bib14]) reported an increased number of CD8+ T cells in the bursa, in the cecal tonsils, and in the lamina propria of the caecum up to 14 D after very virulent IBDV infection, suggesting that the CD8+ T cells are not only activated in the bursa but also in the gut. Our results showed a higher amount, after IBDV vaccination with the immune complex vaccine, of cytotoxic CD8+ T lymphocytes in further lymphoid districts such as the Harderian gland and the trachea. The CD8+ T cell increasing also resulted in an altered proportion in the trachea of the CD4+/CD8+ ratio, that tended to be significantly reduced in the immune-complex IBD vaccine group, compared to the not-vaccinated group. A reduction in the proportion of CD4+/CD8+ and an increase of CD8+, associated with immunological disfunctions, have been also reported in humans during prolonged infections with human immunodeficiency virus and cytomegalovirus ([@bib20]; [@bib21]).

The CTL response has been reported to be critical in the protection of chickens from IBV acute infection ([@bib28]); therefore, it could be speculated that the significant difference of the amount of CD8+ cells observed among groups could be attributed to an higher replication of the IBV vaccines in the immunologically impaired immune-complex vaccinated group.

The results of the in vivo trials performed in SPF broiler chickens coupled with a depth analysis of the repertoire of parameters involved in the immune response to IBDV vaccination suggest that more than one aspect should be considered when choosing the vaccination program, considering the mutual influence that can occur between the different vaccines applied.

Further studies involving commercial chickens could expand upon the results obtained, exploring how the maternally derived antibodies can influence the impact of IBDV vaccination on the chicken immune system.
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